CD22 and acute lymphoblastic leukemia: Thus, in this study, we aimed to investigate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in 23 adult patients with R/R B-ALL who were ineligible for or unwilling to undergo allo-HSCT.